HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings

09 июн 2023 05:30:00 Источник Nasdaq GlobeNewswire

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

25 май 2023 19:00:54 Источник Nasdaq GlobeNewswire

HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting

25 май 2023 18:00:00 Источник Nasdaq GlobeNewswire

HUTCHMED Announces Board of Directors and Board Committee Membership

12 май 2023 04:30:00 Источник Nasdaq GlobeNewswire

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees 

10 май 2023 04:30:00 Источник Nasdaq GlobeNewswire

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

17 апр 2023 20:00:00 Источник Nasdaq GlobeNewswire

HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023

11 апр 2023 20:00:00 Источник Nasdaq GlobeNewswire

Intended Retirement of Independent Non-executive Director

11 апр 2023 04:30:00 Источник Nasdaq GlobeNewswire

HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations

04 апр 2023 05:30:00 Источник Nasdaq GlobeNewswire

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

30 мар 2023 20:00:00 Источник Nasdaq GlobeNewswire

HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China

14 мар 2023 09:30:00 Источник Nasdaq GlobeNewswire

HUTCHMED Confirms No Assets Held at Silicon Valley Bank

12 мар 2023 20:07:31 Источник Nasdaq GlobeNewswire

HUTCHMED Reports 2022 Full Year Results and Provides Business Updates

28 фев 2023 03:30:00 Источник Nasdaq GlobeNewswire

HUTCHMED to Announce 2022 Final Results

31 янв 2023 03:30:00 Источник Nasdaq GlobeNewswire

HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China

23 янв 2023 03:00:55 Источник Nasdaq GlobeNewswire

HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China

18 янв 2023 09:30:00 Источник Nasdaq GlobeNewswire

HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China

03 янв 2023 03:30:00 Источник Nasdaq GlobeNewswire

HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer

19 дек 2022 05:00:00 Источник Nasdaq GlobeNewswire

HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals

14 ноя 2022 19:00:00 Источник Nasdaq GlobeNewswire

HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China

13 ноя 2022 19:00:00 Источник Nasdaq GlobeNewswire